CSO

TECHNOCLONE RECEIVES US FDA MARKETING AUTHORIZATION FOR THE FIRST ADAMTS13 ACTIVITY DIAGNOSTIC TEST

Retrieved on: 
Tuesday, March 5, 2024

WEST CHESTER, Ohio, March 5, 2024 /PRNewswire/ -- Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, world-leading producer of diagnostic tests, equipment, and research products in the field of blood clotting and its exclusive distributor in the USA, DiaPharma Group, Inc., are pleased to announce that the US Food and Drug Administration (FDA) granted De Novo marketing authorization for Technozym ADAMTS13 Activity ELISA.

Key Points: 
  • WEST CHESTER, Ohio, March 5, 2024 /PRNewswire/ -- Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH, world-leading producer of diagnostic tests, equipment, and research products in the field of blood clotting and its exclusive distributor in the USA, DiaPharma Group, Inc., are pleased to announce that the US Food and Drug Administration (FDA) granted De Novo marketing authorization for Technozym ADAMTS13 Activity ELISA.
  • This is the first ADAMTS13 activity test authorized by the FDA.
  • The Technozym ADAMTS13 Activity assay is an enzyme-linked immunosorbent assay (ELISA) intended for the qualitative determination of ADAMTS13 activity in platelet poor human citrated plasma.
  • "In line with our commitment to provide ADAMTS13 diagnostics globally, we are excited about this milestone, having the first ADAMTS13 activity test granted with marketing authorization by the FDA", says Nikolaus Binder, MD, PhD, CSO of Technoclone.

PhotonPharma, Inc. Receives FDA Clearance for a First in Human Clinical Study for Stage III/IV Ovarian Cancer Treatment with the Investigational Autologous Vaccine Therapy, Innocell™

Retrieved on: 
Tuesday, March 5, 2024

These inactivated cells are used in a treatment designed to recruit the patient's own immune system to fight the cancer.

Key Points: 
  • These inactivated cells are used in a treatment designed to recruit the patient's own immune system to fight the cancer.
  • The vaccine therapy will be manufactured at City of Hope's Los Angeles campus in its Biological and Cellular GMP Manufacturing Facility.
  • The Phase 1 clinical trial for Innocell will evaluate its safety, tolerability, and potential immune response indicators in patients with Stage III/IV ovarian cancer.
  • PhotonPharma anticipates initiating patient enrollment in the near future, with the aim of profiling the therapeutic potential of this innovative autologous vaccine therapy.

Clinical Microbiomics adds World-Leading Expertise in Long-Read DNA & RNA Sequencing Technologies with Acquisition of DNASense ApS

Retrieved on: 
Friday, March 1, 2024

The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.

Key Points: 
  • The acquisition expands Clinical Microbiomics' expertise and offering for new segments such as agriculture, industrial, and environmental ecosystems, and it adds cutting-edge long- read DNA- and RNA sequencing technologies to the extensive portfolio of multi-omics technologies for the microbiome field.
  • H. Bjørn Nielsen, CSO of Clinical Microbiomics, "DNASense is a first mover in applying long-read technology broadly across microbiome research and industrial applications.
  • Mads Søndergaard, CEO of DNASense, comments on the synergies: "Joining Clinical Microbiomics is a pivotal moment for DNASense.
  • The DNASense acquisition facilitates expansion into new applications of microbiome science to better understand diverse biological systems and ecological dynamics.

Huawei Launches Talent Development Service Solutions to Accelerate Transformation of Digitally Skilled Talent

Retrieved on: 
Friday, March 1, 2024

Huawei launched its talent development service solutions during the session.

Key Points: 
  • Huawei launched its talent development service solutions during the session.
  • Huawei launched its talent development service solutions, which are aligned with customers' talent development value streams.
  • The solutions can help customers build teams of digitally skilled talent and promote the transformation in infrastructure, O&M, and digital services.
  • Huawei will continue to bridge global wisdom, and collaborate with customers to lead talent development in the intelligent world.

Industry Veteran Caleb Sima to Keynote Identity Management Day 2024 Conference, Registration Now Open

Retrieved on: 
Thursday, February 29, 2024

NEW BRAUNFELS, Texas, Feb. 29, 2024 /PRNewswire/ -- The Identity Defined Security Alliance (IDSA), a nonprofit that provides vendor-neutral education and resources to help organizations reduce the risk of a breach by combining identity and security strategies, today announced registration is now open for the Identity Management Day Virtual Conference 2024. The free one-day event will take place on Identity Management Day, April 9, 2024.

Key Points: 
  • The free one-day event will take place on Identity Management Day, April 9, 2024.
  • The fourth annual Identity Management Day, presented by the IDSA, the Secure Identity Alliance , and IdentityXP , in partnership with the National Cybersecurity Alliance (NCA), and co-chaired by Saviynt , will be a 24-hour-long event.
  • Nominate an Individual or Organization for an Identity Management Award: Recognize individuals and organizations making identity management and security an enabler to business operations while reducing risk.
  • Become an Identity Management Champion : Identity Management Champions have made identity management and security foundational to their mission.

PDW Awarded $6.9M Contract by USSOCOM for Blackwave Next-Generation UAS Communications

Retrieved on: 
Wednesday, February 28, 2024

HUNTSVILLE, Ala., Feb. 28, 2024 /PRNewswire/ -- PDW, creator of the world's most mission-versatile small unmanned aerial system (sUAS), today announced that it was awarded a $6.9M contract from the Special Operations Forces Acquisitions, Technology and Logistics (SOF AT&L) office for delivery of Blackwave, a next-generation radio system specifically designed to overcome contested and congested RF environments.

Key Points: 
  • Blackwave is a secure, digital link that is resistant to intentional and unintentional interference.
  • This system permits critical communications and the operation of small robotics in highly contested environments.
  • Previously tested and challenged by the Joint Vulnerability Assessment Branch (JVAB), Blackwave has been proven to be a durable, tactical wireless link.
  • The partnership between PDW and USSOCOM furthers their commitments to military innovation by solving problems in an evolving battlefield and arming the future warfighter with state-of-the-art technology.

SJC Media Names Optable as Data Management & Collaboration Partner for Privacy-First Advertising

Retrieved on: 
Thursday, February 22, 2024

MONTREAL, Feb. 22, 2024 /PRNewswire/ -- Optable, a leading software-as-a-service (SaaS) data collaboration platform and clean room solution for the advertising ecosystem, has been chosen by SJC Media, publisher of Canada's largest portfolio of media brands including Chatelaine and Maclean's, as its data management and collaboration technology partner.

Key Points: 
  • SJC Media Adopts Optable's Next-Generation Data Management Platform (DMP) for Privacy-First Data Collection, Management, and Activation
    MONTREAL, Feb. 22, 2024 /PRNewswire/ -- Optable , a leading software-as-a-service (SaaS) data collaboration platform and clean room solution for the advertising ecosystem, has been chosen by SJC Media , publisher of Canada's largest portfolio of media brands including Chatelaine and Maclean's, as its data management and collaboration technology partner.
  • Optable's platform will enable SJC Media to collect, manage, and activate data from its own audience for targeted advertising, while prioritizing user privacy.
  • "We believe in putting privacy first, strengthening our roots in first-party data, and fostering genuine collaboration," said Michael Gagliano, Vice President, Audience & Commerce, SJC Media.
  • The Optable DMP will be integrated into SJC Media advertising products starting this month.

Rgenta Therapeutics to Present at the 19th Annual Huntington's Disease Therapeutics Conference

Retrieved on: 
Wednesday, February 21, 2024

CAMBRIDGE, Mass., Feb. 21, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced it will participate at the 19th Annual Huntington's Disease Therapeutics Conference being held February 26-29, 2024, in Palm Springs, California.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 21, 2024 /PRNewswire/ -- Rgenta Therapeutics ("Rgenta" or the "Company") today announced it will participate at the 19th Annual Huntington's Disease Therapeutics Conference being held February 26-29, 2024, in Palm Springs, California.
  • As part of the annual conference, Travis Wager, Ph.D., President & CSO of Rgenta will participate in the Targeting the DNA repair machinery to modulate somatic instability session on Tuesday, February 27, 2024 at 2:00 PM PT.
  • To date, there has been a lack of successful strategies for directly targeting the PMS1 protein with small molecule inhibitors.
  • For more information about the event, please visit the conference website .

Bitsight Unveils Industry's First Fully Integrated Solution for Managing the Entire Third-Party Risk Lifecycle

Retrieved on: 
Wednesday, February 21, 2024

BOSTON, Feb. 21, 2024 /PRNewswire/ -- Bitsight, the leader in cyber risk management, today announced the launch of the industry's first fully-integrated Third-Party Risk Management solution to help enterprise risk and security leaders protect the digital supply chain. By combining Vendor Risk Management and Continuous Monitoring into a single platform, enterprise teams can assess vendor health, manage onboarding, monitor vendor security hygiene, and respond to security incidents.

Key Points: 
  • "Third-party vendors often present the single biggest risk to enterprise security," said Vanessa Jankowski, SVP, Applications & Data Products at Bitsight.
  • "But more than half of risk and security teams lack the tools and people to combat it.
  • High-profile breaches arising from vulnerabilities in integrated providers like MOVEit and SolarWinds have prompted renewed focus on enterprise Third-Party Risk Management.
  • "We've integrated Bitsight Vendor Risk Management into our onboarding and evaluation process, and it's helped us identify the actual risk level associated with vendors."

Genezen Enters Licensing Agreement with CSL for the Cytegrity™ Stable Lentivirus Production System

Retrieved on: 
Wednesday, February 21, 2024

FISHERS, Ind. and BOSTON, Feb. 21, 2024 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary ­­­­stable production system from biotechnology leader CSL.

Key Points: 
  • Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to cutting edge technology for stable and scalable high-titer clinical lentivirus production.
  • and BOSTON, Feb. 21, 2024 /PRNewswire/ -- Genezen, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced licensing of the Cytegrity™ proprietary ­­­­stable production system from biotechnology leader CSL.
  • Cytegrity™ is an advanced inducible stable producer technology designed for the production of lentiviral vectors (LVVs).
  • We have significant, hands-on experience scaling up and producing LVV using this stable production system at our GMP vector facility in Fishers, Indiana.